BioCentury | Mar 9, 2020
Finance

With $22M B round, Numab to build out multispecific mAb pipeline

Following a run of partnerships with Asian companies, Numab has closed a series B round to enable the Swiss biotech to focus on expanding its pipeline of multispecific mAbs. Numab Therapeutics AG announced Monday that...
BioCentury | Dec 14, 2019
Company News

Dec. 13 Company Quick Takes: Horizon, Intercept, Imfinzi, Evenity and Numab-3SBio

FDA panel backs Horizon's eye disease candidate FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously Friday that the benefits of teprotumumab to treat active thyroid eye disease outweigh the potential risks. The mAb against...
BioCentury | Oct 8, 2019
Company News

After remedies to NDA, Intarcia’s diabetes implant under FDA review again

More than two years after well-funded Intarcia received a complete response letter from FDA, an NDA for the company’s implantable pump to treat Type II diabetes is back under the agency’s review. The new PDUFA...
BioCentury | May 2, 2019
Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
BioCentury | Mar 5, 2019
Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
BioCentury | Jun 16, 2017
Company News

Numab, Kaken partner to discover multi-specific antibody for inflammatory disease

Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for an undisclosed inflammatory indication using Numab’s discovery platform. Under the deal, Kaken will fund Numab’s efforts...
BioCentury | Mar 31, 2017
Company News

Numab, Ono deal

Numab granted Ono exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound. Numab’s platform is...
BioCentury | Mar 28, 2017
Company News

Ono, Numab to discover multispecific antibody

Numab Therapeutics AG (Waedensil, Switzerland) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire...
BioCentury | Sep 15, 2016
Financial News

Intarcia raises $215M, expects more next quarter

Diabetes company Intarcia Therapeutics Inc. (Boston, Mass.) raised $215 million in the first close of a series EE round. The company expects to raise more money next quarter in a second, larger close that would...
BioCentury | Sep 25, 2015
Company News

Intarcia expands pipeline with Phoundry acquisition

Intarcia Therapeutics Inc. (Boston, Mass.) acquired Phoundry Pharmaceuticals Inc. (Research Triangle Park, N.C.) for an undisclosed sum, just weeks after Phoundry announced its first seed funding. The deal gives Intarcia a portfolio of optimized peptides,...
Items per page:
1 - 10 of 21
BioCentury | Mar 9, 2020
Finance

With $22M B round, Numab to build out multispecific mAb pipeline

Following a run of partnerships with Asian companies, Numab has closed a series B round to enable the Swiss biotech to focus on expanding its pipeline of multispecific mAbs. Numab Therapeutics AG announced Monday that...
BioCentury | Dec 14, 2019
Company News

Dec. 13 Company Quick Takes: Horizon, Intercept, Imfinzi, Evenity and Numab-3SBio

FDA panel backs Horizon's eye disease candidate FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously Friday that the benefits of teprotumumab to treat active thyroid eye disease outweigh the potential risks. The mAb against...
BioCentury | Oct 8, 2019
Company News

After remedies to NDA, Intarcia’s diabetes implant under FDA review again

More than two years after well-funded Intarcia received a complete response letter from FDA, an NDA for the company’s implantable pump to treat Type II diabetes is back under the agency’s review. The new PDUFA...
BioCentury | May 2, 2019
Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
BioCentury | Mar 5, 2019
Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
BioCentury | Jun 16, 2017
Company News

Numab, Kaken partner to discover multi-specific antibody for inflammatory disease

Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for an undisclosed inflammatory indication using Numab’s discovery platform. Under the deal, Kaken will fund Numab’s efforts...
BioCentury | Mar 31, 2017
Company News

Numab, Ono deal

Numab granted Ono exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire IP rights to the compound. Numab’s platform is...
BioCentury | Mar 28, 2017
Company News

Ono, Numab to discover multispecific antibody

Numab Therapeutics AG (Waedensil, Switzerland) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights to develop and commercialize a multispecific immuno-oncology antibody to be identified using Numab’s discovery platform. Ono also received an option to acquire...
BioCentury | Sep 15, 2016
Financial News

Intarcia raises $215M, expects more next quarter

Diabetes company Intarcia Therapeutics Inc. (Boston, Mass.) raised $215 million in the first close of a series EE round. The company expects to raise more money next quarter in a second, larger close that would...
BioCentury | Sep 25, 2015
Company News

Intarcia expands pipeline with Phoundry acquisition

Intarcia Therapeutics Inc. (Boston, Mass.) acquired Phoundry Pharmaceuticals Inc. (Research Triangle Park, N.C.) for an undisclosed sum, just weeks after Phoundry announced its first seed funding. The deal gives Intarcia a portfolio of optimized peptides,...
Items per page:
1 - 10 of 21